Akshay Sood to Urinary Bladder Neoplasms
This is a "connection" page, showing publications Akshay Sood has written about Urinary Bladder Neoplasms.
Connection Strength
5.634
-
Sood A, Rudzinski JK, Labbate CV, Hensley PJ, Bree KK, Guo CC, Alhalabi O, Campbell MT, Siefker-Radtke AO, Navai N, Dinney CPN, Gao J, Kamat AM. Long-Term Oncological Outcomes in Patients Diagnosed With Nonmetastatic Plasmacytoid Variant of Bladder Cancer: A 20-Year University of Texas MD Anderson Cancer Center Experience. J Urol. 2024 02; 211(2):241-255.
Score: 0.776
-
Sood A, Keeley J, Palma-Zamora I, Novara G, Elshaikh M, Jeong W, Hensley P, Navai N, Peabody JO, Trinh QD, Rogers CG, Menon M, Abdollah F. High-intensity local treatment of clinical node-positive urothelial carcinoma of the bladder alongside systemic chemotherapy improves overall survival. Urol Oncol. 2022 02; 40(2):62.e1-62.e11.
Score: 0.664
-
Sood A, Abdollah F, Cole D, Alanee S. Re: Stenting prior to Cystectomy is an Independent Risk Factor for Upper Urinary Tract Recurrence: B. Kiss, M. A. Furrer, P. Y. Wuethrich, F. C. Burkhard, G. N. Thalmann and B. Roth J Urol 2017;198:1263-1268. J Urol. 2018 04; 199(4):1069-1070.
Score: 0.518
-
Sood A, Klett DE, Abdollah F, Sammon JD, Pucheril D, Menon M, Jeong W, Peabody JO. Robot-assisted partial cystectomy with intraoperative frozen section examination: Evolution and evaluation of a novel technique. Investig Clin Urol. 2016 05; 57(3):221-8.
Score: 0.461
-
Finocchiaro A, Tylecki A, Vigan? S, Bertini A, Ficarra V, Di Trapani E, Salonia A, Briganti A, Montorsi F, Lughezzani G, Buffi N, Sood A, Rogers C, Abdollah F. Socioeconomic disparities and bladder cancer stage at diagnosis: a statewide cohort analysis. JNCI Cancer Spectr. 2025 Jul 01; 9(4).
Score: 0.218
-
Finocchiaro A, Tylecki A, Stephens A, Vigan? S, Bertini A, Briganti A, Montorsi F, Salonia A, Lughezzani G, Buffi N, Ficarra V, Di Trapani E, Sood A, Rogers C, Abdollah F. Socioeconomic disparities and MIBC survival outcome-An analysis of a statewide cohort. World J Urol. 2025 Jun 02; 43(1):349.
Score: 0.217
-
Teplitsky SL, Cranford W, Kim JK, Bell S, Strup S, Allison D, Buchanan A, Myint Z, Strup SE, Martin F, Sood A, Kamat AM, McLouth CJ, Hensley PJ. Prognostic significance of pathologic response to neoadjuvant chemotherapy in muscle-invasive urothelial carcinoma of the bladder with histologic subtype. Urol Oncol. 2025 Sep; 43(9):521.e19-521.e27.
Score: 0.216
-
Steinmetz AR, Pierce M, Martini A, Tholomier C, Manyam G, Chen Y, Sood A, Duplisea JJ, Johnson BA, Czerniak BA, Lee BH, Jagannath C, Yla-Herttuala S, Parker NR, McConkey DJ, Dinney CP, Mokkapati S. Single-cell RNA sequencing analysis identifies acute changes in the tumor microenvironment induced by interferon a gene therapy in a murine bladder cancer model. Front Immunol. 2024; 15:1387229.
Score: 0.208
-
Lobo N, Duan Z, Sood A, Zhao H, Lindskrog SV, Dyrskjot L, Giordano SH, Williams SB, Bree KK, Kamat AM. Sex Disparity in Non-muscle-invasive Bladder Cancer: Pitfalls of Large Population-based Data Sets and Lessons from an Integrated Analysis. Eur Urol Oncol. 2025 Jun; 8(3):608-611.
Score: 0.208
-
Finati M, Stephens A, Chiarelli G, Cirulli GO, Tinsley S, Wang Y, Sood A, Buffi N, Lughezzani G, Salonia A, Briganti A, Montorsi F, Busetto GM, Carrieri G, Rogers C, Abdollah F. Radical cystectomy versus trimodal therapy for muscle-invasive bladder cancer: Analysis of an other-cause mortality matched cohort. Urol Oncol. 2025 01; 43(1):61.e1-61.e9.
Score: 0.206
-
Lobo N, Duan Z, Sood A, Tan WS, Grajales V, Contieri R, Lindskrog SV, Dyrskj?t L, Zhao H, Giordano SH, Williams SB, Bree KK, Kamat AM. Association of Age with Non-muscle-invasive Bladder Cancer: Unearthing a Biological Basis for Epidemiological Disparities? Eur Urol Oncol. 2024 Oct; 7(5):1069-1079.
Score: 0.197
-
Posada JM, Yakirevich E, Kamat AM, Sood A, Jacob JM, Bratslavsky G, Grivas P, Spiess PE, Li R, Necchi A, Mega AE, Golijanin DJ, Pavlick D, Huang RSP, Lin D, Danziger N, Sokol ES, Sivakumar S, Ross JS, Cheng L. Characterizing the Genomic Landscape of the Micropapillary Subtype of Urothelial Carcinoma of the Bladder Harboring Activating Extracellular Mutations of ERBB2. Mod Pathol. 2024 Mar; 37(3):100424.
Score: 0.197
-
Contieri R, Grajales V, Tan WS, Martini A, Sood A, Hensley P, Bree K, Lobo N, Nogueras-Gonzalez GM, Guo CC, Navai N, Dinney CP, Kamat AM. Impact of age >70?years on oncological outcomes in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette-Gu?rin. BJU Int. 2024 01; 133(1):63-70.
Score: 0.191
-
Hensley PJ, Duan Z, Bree K, Sood A, Zhao H, Lobo N, Contieri R, Campbell MT, Guo CC, Navai N, Williams SB, Dinney CP, Kamat AM. Competing mortality risk from second primary malignancy in bladder cancer patients following radical cystectomy: Implications for survivorship. Urol Oncol. 2023 02; 41(2):108.e11-108.e17.
Score: 0.182
-
Corsi NJ, Messing EM, Sood A, Keeley J, Bronkema C, Rakic N, Jamil M, Dalela D, Arora S, Piontkowski AJ, Majdalany SE, Butaney M, Rakic I, Li P, Menon M, Rogers CG, Abdollah F. Risk-Based Assessment Of the Impact Of Intravesical Therapy on Recurrence-Free Survival Rate Following Resection of Suspected Low-grade, Non-muscle-invasive Bladder Cancer (NMIBC): A Southwest Oncology Groups (SWOG) S0337 Posthoc Analysis. Clin Genitourin Cancer. 2022 12; 20(6):e498-e505.
Score: 0.177
-
Jamil ML, Deebajah M, Sood A, Alanee S. Combination of pembrolizumab and BCG treatment after endoscopic ablation of high-risk superficial upper urinary tract urothelial carcinoma in patients not candidates for radical nephroureterectomy: protocol for phase-II study. BMJ Open. 2019 12 03; 9(12):e027066.
Score: 0.148
-
Jamil ML, Deebajah M, Sood A, Robinson K, Rao K, Sana S, Alanee S. Protocol for phase I study of pembrolizumab in combination with Bacillus Calmette-Gu?rin for patients with high-risk non-muscle invasive bladder cancer. BMJ Open. 2019 07 17; 9(7):e028287.
Score: 0.144
-
Holland BC, Sood A, Delfino K, Dynda DI, Ran S, Freed N, Alanee S. Age and sex have no impact on expression levels of markers of immune cell infiltration and immune checkpoint pathways in patients with muscle-invasive urothelial carcinoma of the bladder treated with radical cystectomy. Cancer Immunol Immunother. 2019 Jun; 68(6):991-997.
Score: 0.142
-
Gild P, Wankowicz SA, Sood A, von Landenberg N, Friedlander DF, Alanee S, Chun FKH, Fisch M, Menon M, Trinh QD, Bellmunt J, Abdollah F. Racial disparity in quality of care and overall survival among black vs. white patients with muscle-invasive bladder cancer treated with radical cystectomy: A national cancer database analysis. Urol Oncol. 2018 10; 36(10):469.e1-469.e11.
Score: 0.135
-
Cole AP, Sun M, Lipsitz SR, Sood A, Kibel AS, Trinh QD. Reassessing the value of high-volume cancer care in the era of precision medicine. Cancer. 2018 04 01; 124(7):1319-1321.
Score: 0.130
-
Vetterlein MW, Karabon P, Dalela D, Jindal T, Sood A, Seisen T, Trinh QD, Menon M, Abdollah F. Impact of Baseline Characteristics on the Survival Benefit of High-Intensity Local Treatment in Metastatic Urothelial Carcinoma of the Bladder. Eur Urol Focus. 2018 07; 4(4):568-571.
Score: 0.121
-
Sammon JD, Abdollah F, Klett DE, Pucheril D, Sood A, Trinh QD, Menon M. The diminishing returns of robotic diffusion: complications after robot-assisted radical prostatectomy. BJU Int. 2016 Feb; 117(2):211-2.
Score: 0.108
-
He X, Marchionni L, Hansel DE, Yu W, Sood A, Yang J, Parmigiani G, Matsui W, Berman DM. Differentiation of a highly tumorigenic basal cell compartment in urothelial carcinoma. Stem Cells. 2009 Jul; 27(7):1487-95.
Score: 0.072